NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $0.16 -0.01 (-4.51%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$0.16 0.00 (-0.62%) As of 11/20/2026 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Context Therapeutics Stock (NASDAQ:CNTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Context Therapeutics alerts:Sign Up Key Stats Today's Range$0.16▼$0.1850-Day Range$0.16▼$0.3952-Week Range$0.15▼$3.62Volume1.11 million shsAverage Volume1.61 million shsMarket Capitalization$14.79 millionP/E RatioN/ADividend YieldN/APrice Target$6.40Consensus RatingModerate Buy Company Overview Context Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. The company’s research focuses on bispecific antibodies designed to direct immune cells toward cancer cells. Its pipeline includes CTIM-76, a T-cell-engaging bispecific antibody targeting claudin 6, a protein found on certain tumor cells. Context has also been developing CT-95, which targets mesothelin, another protein expressed by some solid tumors. Founded with an initial focus on therapies for women’s cancers, Context has since broadened its work to address a range of solid tumors. The company is based in the United States and conducts clinical-stage drug development.AI Generated. May Contain Errors. Read More Context Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreCNTX MarketRank™: 1.99285013318 of 5 starsContext Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 623rd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingContext Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialContext Therapeutics has a consensus price target of $6.40, representing about 3,875.2% upside from its current price of $0.16.Amount of Analyst CoverageContext Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($0.44) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.37% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 3.68, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently increased by 9.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for CNTX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Context Therapeutics is held by insiders.Percentage Held by Institutions14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTX Stock News HeadlinesContext Therapeutics Inc. (CNTX) - What Are Analysts Thinking About This Stock?November 13, 2026 | americanbankingnews.comContext Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 22 at 1:00 AM | Profits Run (Ad)Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline ProgressNovember 10, 2026 | globenewswire.comCNTX Updates CT-95 Cancer Study as Trial Is Listed as TerminatedNovember 5, 2026 | tipranks.comContext Therapeutics (CNTX) Stock Forecast & Price TargetNovember 3, 2026 | tipranks.comContext Doses First Patient In Phase 1 For Cancer Drug CT-202September 9, 2026 | rttnews.comContext Doses First Patient In Phase 1 For Cancer Drug CT-202September 9, 2026 | rttnews.comSee More Headlines CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.47 on January 1st, 2026. Since then, CNTX stock has decreased by 89.0% and is now trading at $0.1610. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an IPO on Tuesday, October 19th 2021. The company issued 5,000,000 shares at $5.00 per share. Who are Context Therapeutics' major shareholders? Top institutional investors of Context Therapeutics include State Street Corp (1.58%), Russell Investments Group Ltd. (0.73%), Goldman Sachs Group Inc. (0.45%) and Landscape Capital Management L.L.C. (0.26%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Context Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Palantir Technologies (PLTR). Company Calendar Last Earnings11/10/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CNTX's financial health is in the Red zone, according to TradeSmith. CNTX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CNTX CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees15Year Founded2015Price Target and Rating Average Price Target for Context Therapeutics$6.40 High Price Target$9.00 Low Price Target$4.00 Potential Upside/Downside+3,875.2%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-96.54% Return on Assets-83.59% Debt Debt-to-Equity RatioN/A Current Ratio6.59 Quick Ratio6.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book0.47Miscellaneous Outstanding Shares91,879,000Free Float87,469,000Market Cap$14.79 million OptionableNot Optionable Beta1.77 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:CNTX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredRetirement balance looks fine, so why do you feel behind?Does your retirement balance look fine while you still feel like you're falling behind? On Wednesday, December...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.